Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus

Trial Profile

Linagliptin as a modulator of vascular inflammation in patients with type 2 diabetes mellitus

Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Linagliptin (Primary)
  • Indications Coronary artery disease; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms Lina-Plaque
  • Most Recent Events

    • 02 Dec 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 04 Nov 2014 Planned End Date changed from 1 Jun 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov
    • 04 Nov 2014 Planned primary completion date changed from 1 Jun 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top